Lifesblood Labs. The rest of your life begins now.
Press Release
August 1st. 2008 - Los Angeles, CA - LifesBlood LLC is proud to announce the brand new LifesBlood Labs initiative. Consisting of some of the greatest medical, scientific, and business minds in all of the world, LBL's chief mission will be the development of exciting new technologies and medicinal treatments for the advancement and survival of mankind.
CEO and Founder of LifesBlood, LLC, Dr. Leonard J. Alderman, has been tapped as Director of Medical Research for LifesBlood Labs, and has already promised several breakthroughs in the fields of phlebotomy and regenerative medicine.
Dr. Alderman was proud to announce. "We've managed to draw some of the top most talent from several of the larger firms, and, our "Open Idea" interactvity between departments has already led to same landmark discoveries, which we will be sharing with the world over the coming weeks."
While still in the process of patent and FDA approval, Alderman guarantees that what they've created will be available for public consumption in the near future. "It would be wrong of us to keep these amazing things from those who need them most. We hope to roll out the technologies before the end of 2009."
This marks a change in tactics for the business power house, LifesBlood, LLC, which has remained a closed, private company, choosing to develop products internally, as a clearing house for other corporations, most notably Verdus Pharmaceuticals. "Our relationship with Verdus has been quite fruitful over the years, but, it became clear that our goals had rapidly divurged. We wish Verdus and it's various affiliations nothing but continued success.
CORPORATE INFORMATION
LifesBlood, LLC was formed in 2002 by Dr. Leonard J. Alderman and Ted McKinley, who is the Vice President of Biotherapeutics at Verdus Pharmaceuticals. Alderman bought a majority stake in the company in 2007, parting ways with Verdus and their parent corporation to pursue a new line of inquiry in early 2008. LifesBlood Labs marks Alderman's return to the forefront of scientific research and discovery.